Floatz logo

Galantamine Hydrobromide

Nervous System Disorder

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Nervous System Disorder cohort.

Asset / SponsorPhaseRating
Ginkgolide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3BB
3-N-BUTYLPHTHALIDE
Qianfoshan Hospital
Phase 4BB
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Galantamine Hydrobromide is also rated in:

Alzheimer diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
dementiaDormant
BB
Indicative ·
70 / 100
View asset →
mental disorderDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →